- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
51 result(s) found for: Spike protein.
Displaying page 1 of 3.
EudraCT Number: 2021-001459-15 | Sponsor Protocol Number: HS-2021-02 | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Graz | ||
Full Title: Immune response to COVID-19 Vaccination in people with Diabetes Mellitus - COVAC-DM study | ||
Medical condition: Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002927-39 | Sponsor Protocol Number: BOOST_TX/RESCUE_TX | Start Date*: 2021-06-13 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C... | ||
Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001978-37 | Sponsor Protocol Number: CombiVacS | Start Date*: 2021-04-19 |
Sponsor Name:Instituto de Salud Carlos III. ISCIII | ||
Full Title: A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the safety and immunogenicity of one dose of COMIRNATY in subjects that had received one dose of VAXZEVRIA. | ||
Medical condition: Covid-19 Vaccination | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000988-68 | Sponsor Protocol Number: O2021-1 | Start Date*: 2021-03-31 |
Sponsor Name: Region Stockholm | ||
Full Title: Immune response after covid-19 vaccination in patients with renal failure stadium 4 or 5 . | ||
Medical condition: Renal failure stage 4 and 5. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006172-16 | Sponsor Protocol Number: CoVVacBoost | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study | |||||||||||||
Medical condition: Covid (Coronavirus disease)- 19 immunisation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001357-31 | Sponsor Protocol Number: IIV-478 | Start Date*: 2021-05-03 |
Sponsor Name:National Institute of Health and the Environment | ||
Full Title: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects | ||
Medical condition: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004891-33 | Sponsor Protocol Number: T33/2021 | Start Date*: 2022-04-13 |
Sponsor Name:Turku University Hospital | ||
Full Title: COVID-19 vaccine induced immune response in patients with primary antibody deficiency | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002715-38 | Sponsor Protocol Number: APHP220775 | Start Date*: 2023-03-20 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
Full Title: Immunogenicity and reactogenicity of the Beta-variant recombinant protein booster vaccine (VidPrevtyn Beta, Sanofi) compared to a bivalent mRNA vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech... | ||
Medical condition: Adults who received at least 3 doses of mRNA Covid 19 vaccine (BioNTech-Pfizer and/or Moderna), the last dose received at least 6 months prior to the inclusion in the trial. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000206-17 | Sponsor Protocol Number: COVID19_7 | Start Date*: 2021-03-10 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County, with regard to vaccinations. | ||
Medical condition: Vaccination against COVID-19. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000291-11 | Sponsor Protocol Number: IMRES | Start Date*: 2021-05-30 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Characterization of immune responsiveness after SARS-CoV-2 Vaccination in patients with Immunodeficiency or immunosuppressive therapy (COVID-19) | |||||||||||||
Medical condition: Vaccination against SARS-CoV-2 in immunocompromised patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003591-13 | Sponsor Protocol Number: V503-076 | Start Date*: 2024-05-06 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Conco... | |||||||||||||
Medical condition: Papilloma viral infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001072-15 | Sponsor Protocol Number: COV001 | Start Date*: 2020-03-26 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006960-26 | Sponsor Protocol Number: NOR-LAABis-2022 | Start Date*: 2022-11-04 | ||||||||||||||||
Sponsor Name:Oslo University Hospital - Rikshospitalet | ||||||||||||||||||
Full Title: COVID-19 PROPHYLAXIS IN IMMUNOSUPPRESSED PATIENTS WITH NO/POOR SARS-COV-2 VACCINE RESPONSE USING LONG-ACTING ANTIBODIES (AZD7442) | ||||||||||||||||||
Medical condition: Kidney transplant recipients with suboptimal immune response to previous SARS-CoV-2 vaccinations | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NO (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001993-52 | Sponsor Protocol Number: IMCOVAS | Start Date*: 2021-05-20 |
Sponsor Name:University of Antwerp | ||
Full Title: Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vacc... | ||
Medical condition: Coronavirus disease-19 (COVID-19) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004123-16 | Sponsor Protocol Number: 2019nCoV-302 | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Novavax, Inc. | |||||||||||||
Full Title: A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1™ ... | |||||||||||||
Medical condition: Prevention of COVID-19 caused by SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000795-19 | Sponsor Protocol Number: HIPRA-HH-10 | Start Date*: 2022-03-10 | |||||||||||
Sponsor Name:HIPRA SCIENTIFIC | |||||||||||||
Full Title: A PHASE IIB, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED, MULTI-CENTER, NON-INFERIORITY TRIAL TO ASSESS IMMUNOGENICITY AND SAFETY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION DIME... | |||||||||||||
Medical condition: SARS-COV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001411-82 | Sponsor Protocol Number: HIPRA-HH-1 | Start Date*: 2021-08-11 | |||||||||||
Sponsor Name:LABORATORIOS HIPRA, S.A. | |||||||||||||
Full Title: A phase I/IIa study to evaluate safety and immunogenicity of recombinant protein RBD fusion dimer candidate vaccine against SARS-CoV-2 in adult healthy volunteers. | |||||||||||||
Medical condition: SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000461-33 | Sponsor Protocol Number: P2020_312 | Start Date*: 2021-02-17 |
Sponsor Name:Hopital Erasme, Université Libre de Bruxelles | ||
Full Title: Covid-19: Sars-Cov2 vaccination in hemodialysis patient: a phase IV study of the immunogenicity and its determinants | ||
Medical condition: Chronic hemodialysis patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000412-28 | Sponsor Protocol Number: P2020_284 | Start Date*: 2021-02-17 |
Sponsor Name:Hopital Erasme, Université Libre de Bruxelles | ||
Full Title: COVID-19: Sars-Cov2 vaccination in kidney transplant patient: a phase IV study of the immunogenicity and its determinants | ||
Medical condition: Kidney transplant patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000724-35 | Sponsor Protocol Number: 216912 | Start Date*: 2021-05-11 | ||||||||||||||||
Sponsor Name:Vir Biotechnology, Inc. | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Partici... | ||||||||||||||||||
Medical condition: Non-Hospitalized Participants with Mild to Moderate Coronavirus Disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
